These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 37517217

  • 1. RRAGB-mediated suppression of PI3K/AKT exerts anti-cancer role in glioblastoma.
    Li Q, Liu X, Mao J, Liu S, Hou B, Li K, Fang D.
    Biochem Biophys Res Commun; 2023 Oct 08; 676():149-157. PubMed ID: 37517217
    [Abstract] [Full Text] [Related]

  • 2. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L, Jiang Z, Wang J, Yang N, Qi Q, Zhou W, Feng Z, Li W, Zhang Q, Huang B, Chen A, Zhang D, Zhao P, Li X.
    Oncol Rep; 2019 Aug 08; 42(2):605-614. PubMed ID: 31233190
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. SLC25A32 promotes malignant progression of glioblastoma by activating PI3K-AKT signaling pathway.
    Xue Z, Wang J, Wang Z, Liu J, Zhao J, Liu X, Zhang Y, Liu G, Zhao Z, Li W, Zhang Q, Li X, Huang B, Wang X.
    BMC Cancer; 2023 Jun 26; 23(1):589. PubMed ID: 37365560
    [Abstract] [Full Text] [Related]

  • 7. Anticancer effects of veratramine via the phosphatidylinositol-3-kinase/serine-threonine kinase/mechanistic target of rapamycin and its downstream signaling pathways in human glioblastoma cell lines.
    Kim D, Kwon W, Park S, Kim W, Park JK, Han JE, Cho GJ, Yun S, Han SH, Kim MO, Ryoo ZY, Choi SK.
    Life Sci; 2022 Jan 01; 288():120170. PubMed ID: 34826438
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma.
    Viswanathan A, Kute D, Musa A, Konda Mani S, Sipilä V, Emmert-Streib F, Zubkov FI, Gurbanov AV, Yli-Harja O, Kandhavelu M.
    Eur J Med Chem; 2019 Mar 15; 166():291-303. PubMed ID: 30731398
    [Abstract] [Full Text] [Related]

  • 10. Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3.
    Dai Z, Wang L, Wang X, Zhao B, Zhao W, Bhardwaj SS, Ye J, Yin Z, Zhang J, Zhao S.
    Oncol Rep; 2018 Aug 15; 40(2):867-876. PubMed ID: 29989652
    [Abstract] [Full Text] [Related]

  • 11. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y, Dong L, Bao S, Wang M, Yun Y, Zhu R.
    Biomed Pharmacother; 2016 Dec 15; 84():462-469. PubMed ID: 27685789
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tenacissoside H repressed the progression of glioblastoma by inhibiting the PI3K/Akt/mTOR signaling pathway.
    Dong J, Qian Y, Zhang W, Xu J, Wang L, Fan Z, Jia M, Wei L, Yang H, Luo X, Wang Y, Jiang Y, Huang Z, Wang Y.
    Eur J Pharmacol; 2024 Apr 05; 968():176401. PubMed ID: 38331340
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
    Guan Y, He Y, Lv S, Hou X, Li L, Song J.
    J Drug Target; 2019 Jan 05; 27(1):60-66. PubMed ID: 29768063
    [Abstract] [Full Text] [Related]

  • 20. Up-regulated circular RNA hsa_circ_0067934 contributes to glioblastoma progression through activating PI3K-AKT pathway.
    Xin J, Zhang XY, Sun DK, Tian LQ, Xu P.
    Eur Rev Med Pharmacol Sci; 2019 Apr 05; 23(8):3447-3454. PubMed ID: 31081099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.